Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.
about
Liver transplantation in a patient with primary antiphospholipid syndrome and Budd-Chiari syndrome.Endoscopy reporting standards.Management of dabigatran-induced bleeding: expert statement.Long-term prognosis in patients continuing taking antithrombotics after peptic ulcer bleeding.Algorithms for monitoring warfarin use: Results from Delphi Method.Is it necessary to alter anticoagulation therapy for tooth extraction in patients taking direct oral anticoagulants?
P2860
Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dabigatran etexilate: an oral ...... t of thromboembolic disorders.
@en
Dabigatran etexilate: an oral ...... t of thromboembolic disorders.
@nl
type
label
Dabigatran etexilate: an oral ...... t of thromboembolic disorders.
@en
Dabigatran etexilate: an oral ...... t of thromboembolic disorders.
@nl
prefLabel
Dabigatran etexilate: an oral ...... t of thromboembolic disorders.
@en
Dabigatran etexilate: an oral ...... t of thromboembolic disorders.
@nl
P1476
Dabigatran etexilate: an oral ...... t of thromboembolic disorders.
@en
P2093
Judy W M Cheng
P304
P356
10.1016/J.CLINTHERA.2012.02.022
P577
2012-03-22T00:00:00Z